Drug intelligence / Profile preview

Virless

Development stage
Phase 4
Lead developer
Yung Shin Pharmaceutical Industry
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

Virless is a branded formulation of the antiviral drug acyclovir, a synthetic guanine nucleoside analogue used primarily for the treatment and prophylaxis of herpes simplex virus (HSV) infections and varicella-zoster virus (VZV) infections such as chickenpox and herpes zoster. As an oral or topical antiviral, acyclovir is selectively phosphorylated by viral thymidine kinase in infected cells and subsequently converted to its active triphosphate form, which competitively inhibits viral DNA polymerase and causes chain termination when incorporated into viral DNA, thereby blocking viral DNA synthesis and replication. Clinically, Virless (acyclovir) is indicated for mucocutaneous and genital HSV infections, suppression and prophylaxis of recurrent HSV particularly in immunocompromised patients, and treatment of varicella and herpes zoster, with dosing adjusted for age, renal function, and immune status.[1][5][7][11][15][17]

Brand names
Virless
02

Targets

Herpesvirus DNA polymerase

Beyond the preview

Go deeper on Virless.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virless.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call